Committees’ opinions on applications for authorisation available
The consolidated opinions of the Committees for Risk Assessment and Socio-economic Analysis are now available for:
- Five uses of 4-(1,1,3,3-tetramethylbutyl)phenol, ethoxylated by:
- Lonza Biologics Porriño, SL. and Lonza Biologics, plc.;
- Wallac Oy (use 1, use 2);
- Rentschler Biopharma SE;
- Teva Baltics UAB; and
- One use of 4-nonylphenol, branched and linear, ethoxylated by Sekisui S-lec BV Roermond.